

# CMV pp65 – Recombinant Protein

## human cytomegalovirus

200 µL  
2×1 mL

130-091-824  
130-091-823

### Contents

1. Description
  - 1.1 Background information
  - 1.2 Applications
2. Recommendations for *in vitro* restimulation of pp65-specific T cells with CMV pp65 – Recombinant Protein
  - 2.1 Sample preparation
  - 2.2 Reagent requirements
  - 2.3 *In vitro* restimulation of pp65-specific T cells
3. Examples
  - 3.1 Detection and isolation of viable pp65-specific T cells using MACS® IFN-γ Secretion Assay
  - 3.2 Detection of pp65-specific T cells by intracellular staining of IFN-γ
4. References
5. Appendix

### Warnings

Reagents contain sodium azide. Under acidic conditions sodium azide yields hydrazoic acid, which is extremely toxic. Azide compounds should be diluted with running water before discarding. These precautions are recommended to avoid deposits in plumbing where explosive conditions may develop.

### 1. Description

<b>Components</b>	200 µL CMV pp65 – Recombinant Protein or 2×1 mL CMV pp65 – Recombinant Protein: full-length protein (Swiss-Prot Acc. no. P06725)
<b>Capacity</b>	200 µL for stimulation of up to 2×10 <sup>8</sup> total cells, or 2×1 mL for stimulation of up to 2×10 <sup>9</sup> total cells.
<b>Product format</b>	The recombinant protein is supplied in a solution of 50 mM sodium dihydrogenphosphate, 300 mM NaCl, and 4 M urea.
<b>Purity</b>	>95% as determined by SDS-PAGE analysis. Low endotoxin.
<b>Storage</b>	Store protected from light at 2–8 °C. Do not freeze. The expiration date is indicated on the vial label.

#### 1.1 Background information

Human cytomegalovirus (CMV) is a member of the herpes virus group and belongs to the subfamily of beta-herpes viruses. Between 50–85% of human adults are infected with CMV. Once infected,

the virus persists in the organism. The infection is asymptomatic in healthy individuals, but in immunocompromised patients CMV can cause severe diseases.

pp65 (65 kDa lower matrix phosphoprotein)<sup>1</sup>, also known as glycoprotein 64 or UL83, is a virion tegument protein and the main component of the enveloped subviral particle. pp65 is an immunodominant target of CD4<sup>+</sup> as well as CD8<sup>+</sup> T cell responses to CMV.<sup>2</sup> pp65-specific T cells predominantly produce cytokines like IFN-γ, IL-2, and TNF-α.

CMV pp65 – Recombinant Protein is specially developed for efficient *in vitro* stimulation of pp65-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, for example, causing secretion of effector cytokines. The produced cytokines then allow detection or isolation of pp65-specific T cells. Quantitative, phenotypical, or functional analysis of pp65-specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.

#### 1.2 Applications

- Detection and analysis of pp65-specific CD4<sup>+</sup> and CD8<sup>+</sup> effector/memory T cells, e.g., in PBMCs, by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
- Isolation of viable pp65-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits, the CD154 MicroBead Kit, or the CD137 MicroBead Kit, for example, to be expanded for generation of T cell lines/clones for research on immunotherapy in CMV infection.
- Generation of pp65-specific CD4<sup>+</sup> and CD8<sup>+</sup> effector/memory T cells from naive T cell populations, for example, for research on immunotherapy and vaccination.
- Pulsing of antigen-presenting cells, for example, for research on dendritic cell vaccination.
- Research on antigen delivery by antigen-presenting cells.

### 2. Recommendations for *in vitro* restimulation of pp65-specific T cells with CMV pp65 – Recombinant Protein

#### 2.1 Sample preparation

For induction of cytokine secretion by pp65-specific T cells, best results are achieved by stimulation of fresh PBMCs, whole blood, or other leukocyte-containing single-cell preparations from tissues or cell lines. Alternatively, frozen cell preparations can be used.

▲ **Note:** Remove platelets after density gradient separation. Resuspend cell pellet, fill tube with buffer and mix. Centrifuge at 200×g for 10–15 minutes at 20 °C. Carefully aspirate supernatant.

▲ **Note:** PBMCs may be stored overnight. The cells should be resuspended and incubated in culture medium as described in 2.3 steps 1–3., but without addition of antigen. The antigen is then added to the culture on the next day.

## 2.2 Reagent requirements

- Culture medium, for example, RPMI 1640 (# 130-091-440) containing 5% human serum, e.g., autologous or AB serum (do not use BSA or FBS because of non-specific stimulation!).
- (Optional) Cytokine Secretion Assay Kit. For additional reagent and instrument requirements refer to the data sheet of the respective Cytokine Secretion Assay.
- (Optional) Intracellular cytokine staining, for example, with Anti-IFN- $\gamma$ -FITC (# 130-091-641). For additional reagent requirements refer to the respective data sheet.
- (Optional) CD154 Cytokine Detection Kits, CD154 antibodies, or CD154 MicroBead Kit (# 130-092-658). For more information refer to the respective data sheets.
- (Optional) CD137 MicroBead Kit (# 130-093-476) and CD137-PE (# 130-093-475). For more information refer to the respective data sheets.
- (Optional) CytoStim™ for restimulation of human T cells (# 130-092-172, # 130-092-173). For details refer to the CytoStim data sheet.

## 2.3 *In vitro* restimulation of pp65-specific T cells

▲ Always include a negative control in the experiment. The sample should be treated in exactly the same manner as the stimulated sample but without the addition of stimulants.

▲ A positive control, such as a sample stimulated with CytoStim, may also be included.

▲ Do not use media containing non-human proteins, such as BSA or FBS, because of non-specific stimulation.

1. Wash cells by adding medium and centrifuge at 300 $\times$ g for 10 minutes. Aspirate supernatant completely.
2. Resuspend cells in culture medium at 10<sup>7</sup> cells/mL. Plate cells in dishes at a density of 5 $\times$ 10<sup>6</sup> cells/cm<sup>2</sup> (refer to 5. Appendix: Flask and dish sizes for *in vitro* stimulation of T cells).
3. Mix CMV pp65 – Recombinant Protein thoroughly. Add 10  $\mu$ L of CMV pp65 – Recombinant Protein per mL cell suspension. Mix carefully and incubate cells at 37 °C; 5–7% CO<sub>2</sub>.

**Cytokine Secretion Assay:** Incubate cells for 4–16 hours.

**CD154 MicroBead Kit:** Incubate cells for 4–16 hours.

**CD137 MicroBead Kit:** Incubate cells for 16–24 hours.

**Intracellular cytokine staining antibodies or kits, e.g., CD154/IFN- $\gamma$ /CD4 Detection Kit:** Incubate cells for 2 hours, then add 1  $\mu$ g/mL brefeldin A and incubate for further 4 hours.

4. Collect cells carefully by pipetting up and down when working with smaller volumes or by using a cell scraper. Rinse the dish with cold buffer. Check microscopically for any remaining cells, if necessary, rinse the dish again.


To proceed with the Cytokine Secretion Assay, the CD154 or CD137 MicroBead Kits, or intracellular cytokine staining, please refer to the respective data sheet.

▲ **Note:** When preparing cells for intracellular cytokine staining, fixed cells may be stored at 2–8 °C for up to 1 week.

## 3. Examples


### 3.1 Detection and isolation of viable pp65-specific T cells using MACS® IFN- $\gamma$ Secretion Assay

10<sup>7</sup> human PBMCs of a CMV<sup>+</sup> donor were restimulated with CMV pp65 – Recombinant Protein. pp65-specific cells were stained and magnetically enriched according to their secretion of IFN- $\gamma$  using the IFN- $\gamma$  Secretion Assay – Cell Enrichment and Detection Kit (# 130-054-201). T cells were counterstained for CD4 and CD8 expression. IFN- $\gamma$ -secretion of viable lymphocytes is shown.



### 3.2 Detection of pp65-specific T cells by intracellular staining of IFN- $\gamma$

10<sup>6</sup> human PBMCs of a CMV<sup>+</sup> donor were restimulated with CMV pp65 – Recombinant Protein or without antigen, after 2 hours 1  $\mu$ g/mL of brefeldin A was added. Cells were fixed, permeabilized, and pp65-specific cells were intracellularly stained with Anti-IFN- $\gamma$ -PE (# 130-091-653). T cells were counterstained for CD4 and CD8 expression. IFN- $\gamma$ -production of lymphocytes is shown.



#### 4. References

1. Pande, H. *et al.* (1984) Cloning and physical mapping of a gene fragment coding for a 64- kilodalton major late antigen of human cytomegalovirus. *Proc. Natl. Acad. Sci. USA.* 81: 4965–4969.
2. Kern, F. *et al.* (2002) Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. *J. Infect. Dis.* 185: 1709–1716.

#### 5. Appendix: Flask and dish sizes for *in vitro* stimulation of T cells

For *in vitro* stimulation of T cells (refer to 2.3) the cells should be resuspended in culture medium, containing 5% of human serum, at a dilution of  $10^7$  cells/mL. The cells should be plated at a density of  $5 \times 10^6$  cells/cm<sup>2</sup>. Both the dilution and the cell density are important to assure optimum stimulation.

The following table lists culture plate, dish and flask sizes suitable for different cell numbers. It also indicates the appropriate amount of medium to add.

Total cell number	Medium volume to add	Culture plate	Well diameter
$0.15 \times 10^7$	0.15 mL	96 well	0.64 cm
$0.50 \times 10^7$	0.50 mL	48 well	1.13 cm
$1.00 \times 10^7$	1.00 mL	24 well	1.60 cm
$2.00 \times 10^7$	2.00 mL	12 well	2.26 cm
$5.00 \times 10^7$	5.00 mL	6 well	3.50 cm
Total cell number	Medium volume to add	Culture dish	Dish diameter
$4.5 \times 10^7$	4.5 mL	small	3.5 cm
$10.0 \times 10^7$	10.0 mL	medium	6 cm
$25.0 \times 10^7$	25.0 mL	large	10 cm
$50.0 \times 10^7$	50.0 mL	extra large	15 cm
Total cell number	Medium volume to add	Culture flask	Growth area
$12 \times 10^7$	12 mL	50 mL	25 cm <sup>2</sup>
$40 \times 10^7$	40 mL	250 mL	75 cm <sup>2</sup>
$80 \times 10^7$	80 mL	720 mL	162 cm <sup>2</sup>
$120 \times 10^7$	120 mL	900 mL	225 cm <sup>2</sup>

Refer to [www.miltenyibiotec.com](http://www.miltenyibiotec.com) for all data sheets and protocols. Miltenyi Biotec provides technical support worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

## Legal notices

### Limited product warranty

Miltenyi Biotec B.V. & Co. KG and/or its affiliate(s) warrant this product to be free from material defects in workmanship and materials and to conform substantially with Miltenyi Biotec's published specifications for the product at the time of order, under normal use and conditions in accordance with its applicable documentation, for a period beginning on the date of delivery of the product by Miltenyi Biotec or its authorized distributor and ending on the expiration date of the product's applicable shelf life stated on the product label, packaging or documentation (as applicable) or, in the absence thereof, ONE (1) YEAR from date of delivery ("Product Warranty"). Miltenyi Biotec's Product Warranty is provided subject to the warranty terms as set forth in Miltenyi Biotec's General Terms and Conditions for the Sale of Products and Services available on Miltenyi Biotec's website at [www.miltenyibiotec.com](http://www.miltenyibiotec.com), as in effect at the time of order ("Product Warranty"). Additional terms may apply. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF A PRODUCT IS SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION METHODS.

### Technical information

The technical information, data, protocols, and other statements provided by Miltenyi Biotec in this document are based on information, tests, or experience which Miltenyi Biotec believes to be reliable, but the accuracy or completeness of such information is not guaranteed. Such technical information and data are intended for persons with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. Miltenyi Biotec shall not be liable for any technical or editorial errors or omissions contained herein.

All information and specifications are subject to change without prior notice. Please contact Miltenyi Biotec Technical Support or visit [www.miltenyibiotec.com](http://www.miltenyibiotec.com) for the most up-to-date information on Miltenyi Biotec products.

### Licenses

This product and/or its use may be covered by one or more pending or issued patents and/or may have certain limitations. Certain uses may be excluded by separate terms and conditions. Please contact your local Miltenyi Biotec representative or visit Miltenyi Biotec's website at [www.miltenyibiotec.com](http://www.miltenyibiotec.com) for more information.

The purchase of this product conveys to the customer the non-transferable right to use the purchased amount of the product in research conducted by the customer (whether the customer is an academic or for-profit entity). This product may not be further sold. Additional terms and conditions (including the terms of a Limited Use Label License) may apply.

CUSTOMER'S USE OF THIS PRODUCT MAY REQUIRE ADDITIONAL LICENSES DEPENDING ON THE SPECIFIC APPLICATION. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING FOR ITSELF WHETHER IT HAS ALL APPROPRIATE LICENSES IN PLACE. Miltenyi Biotec provides no warranty that customer's use of this product does not and will not infringe intellectual property rights owned by a third party. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

### Trademarks

CytoStim, MACS, the Miltenyi Biotec logo, and PepTivator are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide.

This product is produced and sold under license from City Of Hope, and is covered under U.S. Patents 6,207,161; 6,133,433; 6,242,567 and foreign equivalents. This product is sold for use only in laboratory research or adoptive immunotherapy. Purchase of this product does not convey a license to use this product in vaccines and/or clinical diagnostics.

Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.